GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response
GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response
复制标题
DOI：
10.1016/j.canlet.2011.05.013
复制
发表时间：
2011-10-01
期刊：
影响因子：
9.7
通讯作者：
Guo, Zhongmin
中科院分区：
文献类型：
--
作者：
Chen, Baishen;Rao, Xi;Guo, Zhongmin
谷胱甘肽过氧化物酶3（GPx3）是一种血浆抗氧化酶，通过灭活活性氧（ROS）、已知的DNA损伤剂和癌症化疗反应介质来维持基因组完整性。在这项研究中，我们证明了GPx3基因启动子高甲基化导致的表达缺失在广泛的人类恶性肿瘤中经常被观察到。此外，GPx3甲基化与头颈癌（HNC）化疗耐药性相关，可作为接受顺铂化疗的HNC患者的潜在预后指标。我们的研究结果支持了这一假设，即抗氧化系统的缺陷可能有助于肿瘤的广泛的人类恶性肿瘤。GPx3甲基化可能与HNC患者的化疗反应和临床结局有关。出版社：Elsevier爱尔兰Ltd.
Glutathione peroxidase 3 (GPx3), a plasma antioxidant enzyme, maintains genomic integrity by inactivating reactive oxygen species (ROS), known DNA-damaging agents and mediators of cancer chemotherapy response. In this study, we demonstrate that loss of GPx3 expression by promoter hypermethylation is frequently observed in a wide spectrum of human malignancies. Furthermore, GPx3 methylation correlates with head and neck cancer (HNC) chemoresistance and may serve as a potential prognostic indicator for HNC patients treated with cisplatin-based chemotherapy. Our findings support the hypothesis that defects in the antioxidant system may contribute to tumorigenesis of a wide spectrum of human malignancies. GPx3 methylation may have implications in chemotherapy response and clinical outcome of HNC patients. Published by Elsevier Ireland Ltd.